490 related articles for article (PubMed ID: 18502338)
1. Management of medullary thyroid carcinoma.
Jiménez C; Hu MI; Gagel RF
Endocrinol Metab Clin North Am; 2008 Jun; 37(2):481-96, x-xi. PubMed ID: 18502338
[TBL] [Abstract][Full Text] [Related]
2. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
[TBL] [Abstract][Full Text] [Related]
3. Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2.
Moore SW; Appfelstaedt J; Zaahl MG
J Pediatr Surg; 2007 Feb; 42(2):326-32. PubMed ID: 17270543
[TBL] [Abstract][Full Text] [Related]
4. [The treatment of medullary thyroid cancer].
Fujita T; Fujimori M
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1627-31. PubMed ID: 19838021
[TBL] [Abstract][Full Text] [Related]
5. New presentation of familial medullary thyroid carcinoma in 87-year-old patient with high-risk RET proto-oncogene codon 620 mutation.
Jaggard MK; MacRae C; Ifeacho S; Robinson S; Tolley NS
J Laryngol Otol; 2009 Jul; 123(7):796-800. PubMed ID: 18771606
[TBL] [Abstract][Full Text] [Related]
6. [Management of multiple endocrine neoplasia syndrome type 2 families in association with rare germline mutations of the RET proto-oncogene].
Fitze G; Saeger HD; Roesner D; Schackert HK
Klin Padiatr; 2004; 216(5):270-6. PubMed ID: 15455293
[TBL] [Abstract][Full Text] [Related]
7. Molecular advances in medullary thyroid cancer diagnostics.
Hubner RA; Houlston RS
Clin Chim Acta; 2006 Aug; 370(1-2):2-8. PubMed ID: 16519882
[TBL] [Abstract][Full Text] [Related]
8. [Thyroid carcinomas and Hirschsprung's disease--10-year experience with molecular genetic testing of the RET proto-oncogene].
Bendlová B; Dvoráková S; Václavíková E; Sýkorová V; Vlcek P; Skába R
Vnitr Lek; 2006 Oct; 52(10):926-34. PubMed ID: 17063805
[TBL] [Abstract][Full Text] [Related]
9. RET mutation status in medullary thyroid cancer(MTC) patients and the significance of genetic screening for mutations in their immediate relatives--a preliminary report.
Menon MM; Simha MR
Indian J Pathol Microbiol; 2005 Apr; 48(2):161-5. PubMed ID: 16758654
[TBL] [Abstract][Full Text] [Related]
10. Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets.
Cerrato A; De Falco V; Santoro M
J Mol Endocrinol; 2009 Oct; 43(4):143-55. PubMed ID: 19383830
[TBL] [Abstract][Full Text] [Related]
11. [Medullary carcinoma of the thyroid: diagnosis and therapy].
Giuffrida D; Ferraù F; Bordonaro R; Mattina M; Priolo D; Aiello RA; Cordio S; Motta S; Failla G
Clin Ter; 2000; 151(1):29-35. PubMed ID: 10822879
[TBL] [Abstract][Full Text] [Related]
12. Association of mitochondrial DNA transversion mutations with familial medullary thyroid carcinoma/multiple endocrine neoplasia type 2 syndrome.
Abu-Amero KK; Alzahrani AS; Zou M; Shi Y
Oncogene; 2006 Feb; 25(5):677-84. PubMed ID: 16205644
[TBL] [Abstract][Full Text] [Related]
13. C-cell hyperplasia and medullary thyroid carcinoma: clinicopathological and genetic correlations in 66 consecutive patients.
Guyétant S; Josselin N; Savagner F; Rohmer V; Michalak S; Saint-André JP
Mod Pathol; 2003 Aug; 16(8):756-63. PubMed ID: 12920219
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and management of medullary thyroid carcinoma.
Massoll N; Mazzaferri EL
Clin Lab Med; 2004 Mar; 24(1):49-83. PubMed ID: 15157557
[TBL] [Abstract][Full Text] [Related]
15. Medullary thyroid carcinoma.
Leboulleux S; Baudin E; Travagli JP; Schlumberger M
Clin Endocrinol (Oxf); 2004 Sep; 61(3):299-310. PubMed ID: 15355445
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and surgical dilemmas in hereditary medullary thyroid carcinoma.
Allen SM; Bodenner D; Suen JY; Richter GT
Laryngoscope; 2009 Jul; 119(7):1303-11. PubMed ID: 19444888
[TBL] [Abstract][Full Text] [Related]
17. An in-frame complex germline mutation in the juxtamembrane intracellular domain causing RET activation in familial medullary thyroid carcinoma.
Cordella D; Muzza M; Alberti L; Colombo P; Travaglini P; Beck-Peccoz P; Fugazzola L; Persani L
Endocr Relat Cancer; 2006 Sep; 13(3):945-53. PubMed ID: 16954442
[TBL] [Abstract][Full Text] [Related]
18. Synergistic effect of oncogenic RET and loss of p18 on medullary thyroid carcinoma development.
van Veelen W; van Gasteren CJ; Acton DS; Franklin DS; Berger R; Lips CJ; Höppener JW
Cancer Res; 2008 Mar; 68(5):1329-37. PubMed ID: 18316595
[TBL] [Abstract][Full Text] [Related]
19. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas.
Dvorakova S; Vaclavikova E; Sykorova V; Vcelak J; Novak Z; Duskova J; Ryska A; Laco J; Cap J; Kodetova D; Kodet R; Krskova L; Vlcek P; Astl J; Vesely D; Bendlova B
Mol Cell Endocrinol; 2008 Mar; 284(1-2):21-7. PubMed ID: 18282654
[TBL] [Abstract][Full Text] [Related]
20. Medullary thyroid cancer.
You YN; Lakhani V; Wells SA; Moley JF
Surg Oncol Clin N Am; 2006 Jul; 15(3):639-60. PubMed ID: 16882502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]